These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 19452042)

  • 1. The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer.
    Schettino C; Bareschino MA; Maione P; Rossi A; Ciardiello F; Gridelli C
    Curr Genomics; 2008 Jun; 9(4):252-62. PubMed ID: 19452042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.
    Huang ZL; Cao X; Luo RZ; Chen YF; Zhu LC; Wen Z
    Oncol Lett; 2016 Jan; 11(1):299-305. PubMed ID: 26870207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
    Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
    Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
    Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival.
    Tantraworasin A; Saeteng S; Lertprasertsuke N; Arayawudhikul N; Kasemsarn C; Patumanond J
    Cancer Manag Res; 2013; 5():327-36. PubMed ID: 24124391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
    Leng XF; Chen MW; Xian L; Dai L; Ma GY; Li MH
    J Exp Clin Cancer Res; 2012 Mar; 31(1):25. PubMed ID: 22439756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of the mRNA expression of
    Sun S; Shi W; Wu Z; Zhang G; Yang BO; Jiao S
    Exp Ther Med; 2015 Sep; 10(3):937-941. PubMed ID: 26622418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
    Yan D; Wei P; An G; Chen W
    J Cardiothorac Surg; 2013 Jun; 8():149. PubMed ID: 23759026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer.
    Rosell R; Skrzypski M; Jassem E; Taron M; Bartolucci R; Sanchez JJ; Mendez P; Chaib I; Perez-Roca L; Szymanowska A; Rzyman W; Puma F; Kobierska-Gulida G; Farabi R; Jassem J
    PLoS One; 2007 Nov; 2(11):e1129. PubMed ID: 17987116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of genetic markers on survival in non-small cell lung cancer.
    Rosell R; Taron M; Camps C; López-Vivanco G
    Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
    Ceppi P; Volante M; Novello S; Rapa I; Danenberg KD; Danenberg PV; Cambieri A; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
    Ann Oncol; 2006 Dec; 17(12):1818-25. PubMed ID: 16980606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
    Sève P; Lai R; Ding K; Winton T; Butts C; Mackey J; Dumontet C; Dabbagh L; Aviel-Ronen S; Seymour L; Whitehead M; Tsao MS; Shepherd FA; Reiman T
    Clin Cancer Res; 2007 Feb; 13(3):994-9. PubMed ID: 17289895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
    Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
    Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
    Lafuente-Sanchis A; Zúñiga Á; Galbis JM; Cremades A; Estors M; Martínez-Hernández NJ; Carretero J
    Clin Transl Oncol; 2016 Aug; 18(8):798-804. PubMed ID: 26542178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M; Choi YD; Cho HJ; Ban HJ; Oh IJ; Kim KS; Song SY; Na KJ; Ahn SJ; Choi S; Kim YC
    Respirology; 2012 Jan; 17(1):127-33. PubMed ID: 21899657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zhao H; Zhang H; Du Y; Gu X
    Tumour Biol; 2014 Dec; 35(12):12679-88. PubMed ID: 25227663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
    Su C; Zhou S; Zhang L; Ren S; Xu J; Zhang J; Lv M; Zhang J; Zhou C
    Med Oncol; 2011 Dec; 28(4):1411-7. PubMed ID: 20467918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of ERCC1 and class III ß-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy.
    Zhang S; Li Q; Zhang Q; Wang J; Zhang H; Zhang Z; Wang Q; Yang X; Gu Y; Zhang H
    Int J Biol Markers; 2010; 25(3):141-9. PubMed ID: 20878620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic Analysis of ERCC1, RRM1 and p53 Expressions in Postoperative Stage I-II Lung Cancer.].
    Wang H; Feng J; Zhang X; Yang X; He W; Sha H; Han B
    Zhongguo Fei Ai Za Zhi; 2009 May; 12(5):387-95. PubMed ID: 20719132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.